The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori.

Autor: Lecube A; Endocrinology and Nutrition Department, EASO Collaborating Centre for Obesity Management, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain.; CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBEREM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Valladares S; Endocrinology and Nutrition Department, EASO Collaborating Centre for Obesity Management, Vall d'Hebron University Hospital, Vall d'Hebron Institut de Recerca (VHIR), Autonomous University of Barcelona, Barcelona, Spain., López-Cano C; Endocrinology and Nutrition Department, EASO Collaborating Centre for Obesity Management, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain., Gutiérrez L; Endocrinology and Nutrition Department, EASO Collaborating Centre for Obesity Management, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain., Ciudin A; Endocrinology and Nutrition Department, EASO Collaborating Centre for Obesity Management, Vall d'Hebron University Hospital, Vall d'Hebron Institut de Recerca (VHIR), Autonomous University of Barcelona, Barcelona, Spain., Fort JM; Endocrine, Bariatric and Metabolic Surgery Unit, IFSO Centre of Excellence, Vall d'Hebron University Hospital, Vall d'Hebron Institut de Recerca (VHIR), Autonomous University of Barcelona, Barcelona, Spain., Reñé JM; Gastroenterology Department. Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain., Matias-Guiu X; Department of Pathology and Molecular Genetics, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain., de Torres I; Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institut de Recerca (VHIR), Autonomous University of Barcelona, Barcelona, Spain., Bueno M; Endocrinology and Nutrition Department, EASO Collaborating Centre for Obesity Management, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain., Pallarés J; Department of Pathology and Molecular Genetics, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain., Baena JA; Gastrointestinal Surgery Department. Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica (IRB) and University of Lleida, Lleida, Spain.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2016 Nov 28; Vol. 11 (11), pp. e0166741. Date of Electronic Publication: 2016 Nov 28 (Print Publication: 2016).
DOI: 10.1371/journal.pone.0166741
Abstrakt: Background: Helicobacter pylory (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist.
Material and Methods: Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 subjects.
Results: Both impaired fasting glucose and T2D were similar when comparing subjects with and without HP infection (24.2% vs. 22%, p = 0.290 and 29.4% vs. 29.1%, p = 0.916, respectively), with no differences between groups in the HOMA-IR, lipid profile neither inflammatory parameters. However, HP infection was higher among subjects with a BMI ≥ 40.0 kg/m2 in comparison with lower degrees of obesity (71.7% vs. 60.0%, p = 0.041). In addition, subjects without HP infection showed higher degrees of steatosis (44.1±26.4% vs. 32.0±20.7%, p = 0.038), as well as a lower prevalence of non-alcoholic steatohepatitis (9.3% vs. 30.7%, p = 0.023).
Conclusions: In patients with morbid obesity, HP infection does not seem to be associated with abnormal carbohydrate metabolism. In addition, less advanced degrees of non-alcoholic fatty disease were observed. We suggest that low-grade inflammation that accompanies obesity mitigates the diabetogenic effect of HP, so the presence of obesity should be considered in studies that evaluate the HP metabolic effects.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz: